ArticleCureus2025
Long-Term Survival After Radical Resection of Rectal Cancer With Synchronous Solitary Rib Metastasis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synchronous bone metastasis from rectal cancer is exceedingly uncommon, typically associated with poor prognosis, and lacks a standardized treatment strategy. We report the case of a 67-year-old woman who was asymptomatic and referred for evaluation after a positive fecal occult blood test at screening. Staging work-up revealed rectal cancer with a solitary synchronous metastasis in the left fourth rib. The rib tumor was resected with chest wall reconstruction for both diagnostic confirmation and local control, followed 52 days later by robot-assisted low anterior resection of the primary lesion. R0 resection was achieved for both sites. Considering the risk of occult systemic disease, adjuvant chemotherapy with capecitabine plus oxaliplatin (CAPOX) and bevacizumab was initiated, subsequently switched to capecitabine plus bevacizumab, and continued for two years. The patient remains disease-free five years after primary tumor resection. This case suggests that, in carefully selected patients with solitary synchronous bone metastasis from rectal cancer, combined radical resection and systemic therapy may provide long-term disease control and survival benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.